Biocon Biologics launches biosimilar ‘Hulio’ in USA
HULIO® (adalimumab-fkjp) injection, a biosimilar to Humira® (adalimumab) has been introduced in the United States after five years of experience in Europe and two years in Canada.
HULIO® (adalimumab-fkjp) injection, a biosimilar to Humira® (adalimumab) has been introduced in the United States after five years of experience in Europe and two years in Canada.